Literature DB >> 16972894

Ocular autoimmunity: the price of privilege?

Rachel R Caspi1.   

Abstract

The eye is the prototypic immune-privileged organ. Its antigens were once believed to be expressed exclusively in the eye, which resides behind an efficient blood-organ barrier, and were believed to be unknown to the immune system. Self-tolerance to ocular components was therefore believed to be based not on immune tolerance but on immune ignorance. It is now known that the relationship between the immune system and the eye is much more complex. On the one hand, immune privilege is now known to involve not only sequestration but also active mechanisms that (i) inhibit innate and adaptive immune processes within the eye and (ii) shape the response that develops systemically to antigens released from the eye. On the other hand, retinal antigens are found in the thymus and have been shown to shape the eye-specific T-cell repertoire. However, thymic elimination of self-reactive T cells is incomplete, and such 'escapee' T cells are tolerized in the periphery as they recirculate through the body by encounter with self-antigen in healthy tissues. Due to the relative inaccessibility of the healthy eye to the immune system, peripheral tolerance mechanisms may not operate efficiently for ocular antigens, leaving a weak link in the homeostasis of tolerance. The case shall be made that although immune privilege protects vision by keeping the immune system at bay, a potential for developing destructive anti-retinal autoimmunity may be the price for the day-to-day protection afforded by immune privilege against inflammatory insults.

Entities:  

Mesh:

Year:  2006        PMID: 16972894     DOI: 10.1111/j.1600-065X.2006.00439.x

Source DB:  PubMed          Journal:  Immunol Rev        ISSN: 0105-2896            Impact factor:   12.988


  52 in total

1.  CXCL10 is required to maintain T-cell populations and to control parasite replication during chronic ocular toxoplasmosis.

Authors:  Kazumi Norose; Akitoshi Kikumura; Andrew D Luster; Christopher A Hunter; Tajie H Harris
Journal:  Invest Ophthalmol Vis Sci       Date:  2011-01-21       Impact factor: 4.799

Review 2.  T-cell migration: a naive paradigm?

Authors:  Stephen Cose
Journal:  Immunology       Date:  2007-01       Impact factor: 7.397

Review 3.  In vivo imaging of the immune response in the eye.

Authors:  Doran B Spencer; Ellen J Lee; Tatsushi Kawaguchi; James T Rosenbaum
Journal:  Semin Immunopathol       Date:  2008-03-05       Impact factor: 9.623

Review 4.  Immunity and Toxoplasma retinochoroiditis.

Authors:  G R Wallace; M R Stanford
Journal:  Clin Exp Immunol       Date:  2008-06-28       Impact factor: 4.330

Review 5.  Gut microbiota as a source of a surrogate antigen that triggers autoimmunity in an immune privileged site.

Authors:  Carlos R Zárate-Bladés; Reiko Horai; Mary J Mattapallil; Nadim J Ajami; Matthew Wong; Joseph F Petrosino; Kikuji Itoh; Chi-Chao Chan; Rachel R Caspi
Journal:  Gut Microbes       Date:  2017-01-03

Review 6.  Tissue-based class control: the other side of tolerance.

Authors:  Polly Matzinger; Tirumalai Kamala
Journal:  Nat Rev Immunol       Date:  2011-03       Impact factor: 53.106

7.  Understanding autoimmune uveitis through animal models. The Friedenwald Lecture.

Authors:  Rachel R Caspi
Journal:  Invest Ophthalmol Vis Sci       Date:  2011-03-30       Impact factor: 4.799

Review 8.  Tregs and infections: on the potential value of modifying their function.

Authors:  Sharvan Sehrawat; Barry T Rouse
Journal:  J Leukoc Biol       Date:  2011-09-13       Impact factor: 4.962

9.  A new look at immune privilege of the eye: dual role for the vision-related molecule retinoic acid.

Authors:  Ru Zhou; Reiko Horai; Mary J Mattapallil; Rachel R Caspi
Journal:  J Immunol       Date:  2011-09-14       Impact factor: 5.422

Review 10.  Taming the tiger by the tail: modulation of DNA damage responses by telomeres.

Authors:  David Lydall
Journal:  EMBO J       Date:  2009-07-23       Impact factor: 11.598

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.